GlassScriptPhysician profile
Rabin B Rahmani
NPI 1457514044
$155,259.06
in general payments reported to CMS, 2019-2025
36 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,891 · 2021: $43K · 2022: $36K · 2023: $21K · 2024: $17K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $4,394 · Consulting Fee: $1,500 · Travel and Lodging: $1,212 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,725.00 |
| Food and Beverage | $4,394.00 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,211.57 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $83,267.33 | 2021-2024 | Zeposia |
| Abbvie INC. | $32,808.06 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $23,507.85 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10,194.62 | 2019-2023 | Xifaxan, Trulance |
| Celgene Corporation | $2,710.02 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $543.59 | 2019-2025 | Epclusa |
| Pfizer INC. | $305.22 | 2019-2025 | |
| Janssen Biotech, INC. | $240.56 | 2020-2025 | Tremfya, Stelara |
| Intra-Sana Laboratories | $159.93 | 2021-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ucb, INC. | $151.66 | 2019 | |
| Aimmune Therapeutics, INC. | $128.68 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $125.49 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $124.99 | 2019 | |
| Boston Scientific Corporation | $109.89 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $87.02 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $71.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.83 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $52.61 | 2024-2025 | Resmetirom, Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $47.08 | 2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $39.36 | 2022-2023 | |
| Lilly USA, LLC | $39.10 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $37.79 | 2021 | |
| Ironwood Pharmaceuticals, INC | $34.50 | 2020-2022 | |
| Theratechnologies INC. | $31.98 | 2024 | Trogarzo, Egrifta |
| Genzyme Corporation | $30.37 | 2024 | |
| Currax Pharmaceuticals LLC | $28.96 | 2021-2022 | |
| Covidien LP | $28.93 | 2019 | |
| Intercept Pharmaceuticals, INC. | $24.18 | 2022 | |
| Vivus LLC | $21.97 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.81 | 2025 | Iqirvo |
| Qol Medical, LLC | $20.73 | 2022 | |
| Allergan, INC. | $19.94 | 2019 | |
| Concordia Pharmaceuticals INC. | $19.70 | 2019 | |
| Medline Industries LP | $14.50 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabin Rahmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.